晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02228 晶泰控股

休市中 08-28 16:08:33

7.600

+0.140

+1.88%

最高7.820	最低7.440	成交量6,814万
今开7.500	昨收7.460	日振幅5.09%
总市值327.03亿	流通市值327.03亿	总股本43.03亿
成交额5.23亿	换手率1.58%	流通股本43.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02228","market":"HK","secType":"STK","nameCN":"晶泰控股","latestPrice":7.6,"timestamp":1787904513005,"preClose":7.46,"halted":0,"volume":68139769,"delay":0,"changeRate":0.01876675603217154,"floatShares":4303000000,"shares":4303000000,"eps":0.03,"marketStatus":"休市中","change":0.14,"latestTime":"08-28 16:08:33","open":7.5,"high":7.82,"low":7.44,"amount":522704031,"amplitude":0.050938,"askPrice":7.605,"askSize":75000,"bidPrice":7.6,"bidSize":53000,"shortable":3,"etf":0,"ttmEps":-0.056,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788139800000},"marketStatusCode":7,"adr":0,"listingDate":1718208000000,"exchange":"SEHK","adjPreClose":7.46,"openAndCloseTimeList":[[1787880600000,1787889600000],[1787893200000,1787904000000]],"volumeRatio":1.4554766765467089,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02228/wiki","defaultTab":"wiki","newsList":[{"id":"1134683447","title":"异动解读｜晶泰控股盘中下跌5.59%，中期由盈转亏叠加前日板块大涨后获利回吐","url":"https://stock-news.laohu8.com/highlight/detail?id=1134683447","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134683447?lang=zh_cn&edition=full","pubTime":"2026-08-21 09:43","pubTimestamp":1787276602,"startTime":"0","endTime":"0","summary":"8月21日，晶泰控股盘中下跌5.59%，报7.595港元，成交额9982.35万港元。研发开支3.68亿元，同比增长66%，主因加大自主实验室及在研管线投入。此外，公司股价前一交易日受mRNA突破消息带动板块联动大涨11.27%，短期获利盘集中回吐形成抛压。晶泰控股是一家AI驱动的药物及材料科学研发平台公司，主要从事药物发现解决方案及智能自动化解决方案业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"晶泰控股由盈转亏，股价承压回落","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661309236","title":"直击业绩会丨晶泰控股上半年由盈转亏：加码自研管线投入，AI制药“卖水人”要亲自下场“淘金”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2661309236","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661309236?lang=zh_cn&edition=full","pubTime":"2026-08-21 00:13","pubTimestamp":1787242410,"startTime":"0","endTime":"0","summary":"8月19日晚间，港股AI制药龙头晶泰控股（02228.HK）交出了2026年中期“成绩单”。报告期内，公司实现营业收入3.94亿元，同比下降约23.9%；期内净亏损为2.25亿元，而去年同期净利润为7560.9万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608213848232569.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608213848232569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AIPO","AGIX","BK1617","QTOC","BK1191","VTHR","ARTY","02228","BK1574","01477","CHAT","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660340615","title":"晶泰科技(02228)2026中期业绩解码：AI4S商业化高速突破，多模态管线加速兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2660340615","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660340615?lang=zh_cn&edition=full","pubTime":"2026-08-20 14:19","pubTimestamp":1787206774,"startTime":"0","endTime":"0","summary":"8月19日，晶泰科技发布2026年中期业绩公告。这是晶泰科技从“AI制药服务商”升级为“贯通数字研发与物理实验的AI4S平台”的第一份中报。截至2026年6月30日，公司现金余额合计86.71亿元，充沛的资金储备为持续研发投入提供保障，巩固公司在AI4S领域领先地位。公司搭建行业领先的全流程AI自主决策实验合成能力，相关业务实现高速增长。相较之下，晶泰科技同时拥有真实落地业务场景、确认收入以及高速迭代的管线储备。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1617","BK1141","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660477197","title":"mRNA领域重大突破！创新药概念股飙升，云顶新耀飙升55%，晶泰控股、金斯瑞大涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660477197","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660477197?lang=zh_cn&edition=full","pubTime":"2026-08-20 10:17","pubTimestamp":1787192273,"startTime":"0","endTime":"0","summary":"消息面上，美国制药企业默沙东和莫德纳周三宣布，其实验性信使核糖核酸皮肤癌疫苗在最后阶段临床试验中取得积极结果。专家认为，这是治疗此类癌症的一项“重大突破”。这款名为“intismeran autogene”的新疗法采用mRNA技术。该技术此前已被用于研制新冠疫苗。研究人员多年来一直尝试开发基于mRNA技术的癌症疗法，此次三期临床试验取得积极结果尚属首次。","market":"us","thumbnail":"http://imgcloud.jrjimg.cn/2026/08/cms_20260820101753777.jpg","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2026/08/cms_20260820101753777.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/08/20101758183255.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06978","BK1583","BK1574","BK1617","IBBQ","MEDX","LNGR","BK1161","159992","02228","BK1141","01952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162366260","title":"港股创新药概念股集体走强，中国生物制药涨超20%，石药集团涨超16%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162366260","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162366260?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:59","pubTimestamp":1787191169,"startTime":"0","endTime":"0","summary":"8月20日，港股创新药概念股集体走强，$中国生物制药(01177)$涨超20%，$石药集团(01093)$涨超16%，$晶泰控股(02228)$、$金斯瑞生物科技(01548)$涨超12%，$乐普生物(02157)$、$康方生物(09926)$涨超11%，$荣昌生物(09995)$、$复星医药(02196)$涨超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348783233.USD","LU0348825331.USD","LU1152091168.USD","LU0348766576.USD","LU1226287529.USD","LNGR","LU2778985437.USD","IE00BZ08YT58.USD","02228","LU1969619763.USD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU0634319403.HKD","LU1008478684.HKD","SG9999004220.SGD","VXUS","BK1141","LU2476274308.USD","KURE","LU0348827113.USD","LU1226287875.USD","01548","02196","BK1191","LU0140636845.USD","BK1161","LU2328871848.SGD","LU0348735423.USD","LU0067412154.USD","BK1521","LU1951186391.HKD","IE00B031HY20.USD","06978","BK1576","LU1807302812.USD","IE00BZ08YS42.EUR","LU0561508036.HKD","LU0348784397.USD","LU0417516571.SGD","BK1515","LU2039709279.SGD","BK4588","LU1961090484.USD","HK0000320264.USD","02157","LU2476274720.SGD","KCAI","HK0000306685.HKD","LU1993786604.SGD","HK0000320223.HKD","01093","LU0417516902.SGD","09995","LU1813983027.USD","LU0315179316.USD","LU1226287792.SGD","LU1960683339.HKD","01177","LU1226288170.HKD","159992","LU2399975544.HKD","BK1593","LU0501845795.SGD","LU1720050803.USD","LU2488822045.USD","LU0314109678.HKD","MEDX","IE00B543WZ88.USD","LU0540923850.HKD","LU1152091754.HKD","IBBQ","LU0417516738.SGD","BK1589","IE0008368742.USD","LU0072913022.USD","IE00BPRC5H50.USD","BK1617","BK1583","LU0880133367.SGD","LU1328277881.USD","LU1226288253.USD","BK1574","HK0000165453.HKD","LU1794554557.SGD","09926","IE0008369823.USD","HK0000306701.USD","BK4585","LU0348767384.USD","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146294369","title":"异动解读｜晶泰控股盘中上涨9.96%，中期业绩剔除高基数后主业增长73.8%获市场认可","url":"https://stock-news.laohu8.com/highlight/detail?id=1146294369","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146294369?lang=zh_cn&edition=full","pubTime":"2026-08-20 09:31","pubTimestamp":1787189477,"startTime":"0","endTime":"0","summary":"8月20日，晶泰控股盘中上涨9.96%，报7.905港元，成交额1752.51万港元。但剔除去年同期确认的5100万美元大额管线授权首付款高基数影响后，公司核心业务收入同比增长73.8%，AI4S智慧解决方案业务同比增长136.4%。此外，公司披露管线进展积极，已达成潜在总金额超4亿美元的AI药物发现战略合作，叠加同业英矽智能、金斯瑞等板块个股同步走强，市场对其主业高速增长给予正面定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"晶泰控股盘中上涨9.96%，中期业绩剔除高基数后主业增长73.8%获市场认可","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660444997","title":"晶泰控股(02228)发布中期业绩 收入3.94亿元 研发开支同比增加66.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660444997","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660444997?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:17","pubTimestamp":1787134678,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股(02228)发布截至20266月30日止六个月的中期业绩，收入3.94亿元(人民币，下同);研发开支3.68亿元，同比增加66.05%;股东应占亏损2.52亿元;每股基本亏损6分。公告称，收入同比减少主要由于去年同期确认大额管线授权收入，形成较高比较基数。剔除该影响后，公司的收入实现高速增长，同比增长73.8%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1617","02228","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146460810","title":"晶泰控股（02228）发布2026年中报：营收3.94亿元，同比降23.9%，研发投入增长66%","url":"https://stock-news.laohu8.com/highlight/detail?id=1146460810","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1146460810?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:16","pubTimestamp":1787134564,"startTime":"0","endTime":"0","summary":"2026年8月19日，晶泰控股有限公司披露截至2026年6月30日止六个月未经审计的中期业绩。期内公司实现收入3.94亿元，同比下降23.9%。公司解释称，上年同期确认一笔5,100万美元的管线授权首付款导致基数较高；若剔除此因素，收入同比增长73.8%。受收入结构变化及研发投入加大影响，期内公司录得经营亏损2.54亿元；净亏损2.25亿元。经调整后，公司净亏损1.06亿元，调整项目包括0.66亿元的股份支付及0.53亿元的可转换债券利息费用。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125590102","title":"异动解读｜晶泰控股盘中下跌5.62%，中期业绩披露前夕市场抢跑抛压集中释放","url":"https://stock-news.laohu8.com/highlight/detail?id=1125590102","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125590102?lang=zh_cn&edition=full","pubTime":"2026-08-18 13:15","pubTimestamp":1787030142,"startTime":"0","endTime":"0","summary":"8月18日，晶泰控股盘中下跌5.62%，报7.475港元，成交额2.47亿港元。收入预计3.8亿至4亿元，同比下滑逾22%，主因去年同期确认一项大额管线授权首付款5100万美元形成高基数；同时研发费用不低于3.4亿元，同比增长超50%。业绩窗口临近叠加亏损预期明确，资金提前离场避险。同行业中，英矽智能同日跌7.56%，AI制药板块整体承压。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660073001","title":"再获\"医药界诺贝尔奖\"提名！晶泰科技孵化企业莱芒生物、默达生物共同入围2026盖伦奖","url":"https://stock-news.laohu8.com/highlight/detail?id=2660073001","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660073001?lang=zh_cn&edition=full","pubTime":"2026-08-17 12:59","pubTimestamp":1786942740,"startTime":"0","endTime":"0","summary":"晶泰科技孵化企业莱芒生物与默达生物双双入围\"最佳初创公司\" 奖项。这是继 2025 年晶泰孵化企业希格生科获得 \"最佳生物技术产品奖\" 提名后，晶泰生态圈企业连续第二年登上盖伦奖榜单。晶泰科技孵化企业莱芒生物与默达生物双双入围 盖伦奖“最佳初创公司” 奖项  盖伦奖创立于 1970 年，旨在表彰能显著改善人类健康的杰出科学创新，是全球制药和生物医学领域最高荣誉之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5027293_ZH27293_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5027293_ZH27293_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1617","BK1141","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659299118","title":"创新药概念集体回调 康方生物（09926）跌6.85%、维亚生物（01873）跌6.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659299118","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659299118?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:51","pubTimestamp":1786686711,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念集体回调，康方生物 跌6.85%，维亚生物跌6.33%，思路迪医药股份跌6.15%，恒瑞医药跌5.10%，晶泰控股跌4.88%，凯莱英跌4.67%，亚盛医药跌4.04%，药明康德跌3.94%，百济神州跌3.92%。西南证券表示，CXO+创新药放量领涨，8-9月有望迎来业绩+临床数据共振。从产业链的角度，CXO板块投融资改善明显，26H1中国/全球医疗健康投融资分别676.47亿元/2416.43亿元，ADC、多肽、细胞基因治疗等新药物形式赛道持续火热，头部CXO公司海外订单复苏明显。","market":"other","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988233","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821","LU0348827113.USD","LU1794554557.SGD","LU0327786744.USD","IBBQ","LU1719994722.HKD","LU1961090484.USD","02359","06855","BK1588","LU1720050803.USD","01873","LU0307460666.USD","06160","LNGR","02228","LU0228659784.USD","LU0708995583.HKD","KURE","LU0572944931.SGD","LU2476274308.USD","LU2476274720.SGD","01244","BK1576","LU2242644610.SGD","01276","LU2778985437.USD","LU0359202008.SGD","BK1141","06978","BK1574","LU0359201612.USD","09926","LU0348783233.USD","IE00B543WZ88.USD","LU1770034418.SGD","LU0634319403.HKD","159992","LU0828237510.HKD","LU2399975544.HKD","LU0348766576.USD","LU0561508036.HKD","LU0588546209.SGD","MEDX","LU1251922891.USD","LU0052750758.USD","LU2045819591.USD","LU0348784397.USD","IE00B5MMRT66.SGD","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184084820","title":"异动解读｜晶泰控股盘中下跌5.01%，板块集体回调叠加业绩窗口期承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1184084820","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184084820?lang=zh_cn&edition=full","pubTime":"2026-08-14 13:20","pubTimestamp":1786684803,"startTime":"0","endTime":"0","summary":"8月14日，晶泰控股盘中下跌5.01%，报7.78港元，成交额2.5亿港元。消息面上，生命科学工具和服务板块今日集体走弱，金斯瑞生物科技跌5.93%、英矽智能跌5.52%、药明康德跌3.4%、药明合联跌3.16%，AI制药赛道资金回落明显。此前公司连续多日强势上涨（8月10日至11日累计涨幅超13%），短期获利盘集中涌出。同时，公司8月19日即将披露中期业绩，此前已预告上半年由盈转亏、净亏损约2.15亿至2.75亿元人民币，业绩窗口期临近加剧市场谨慎情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659199950","title":"【券商聚焦】中信建投：AI制药大有可为，产业链有望持续受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2659199950","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659199950?lang=zh_cn&edition=full","pubTime":"2026-08-14 08:58","pubTimestamp":1786669118,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指出，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。传统药物开发过程花费时间长成本高，且成功率较低，随着已有靶点的新药陆续获批，新药开发难度逐渐上升。近年来AI特别是深度学习的发展，促进了其在包括靶点筛选、分子生成及优化、ADMET预测、晶型预测以及合成路线筛选等的应用，AI用于大分子药物的开发投入也持续增长。AIDD有望重塑早期药物发现的流程，大大加速早期药物筛选的效率及成功率，相关干实验投入的增加以及对湿实验需求持续的增长，有望为下游产业链持续带来增量。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZmQ4YWNjMjZmNDUwZDg4ZTlkYjEwZTY1NmI3NmEzMzkwOTI4OTA5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988188","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348735423.USD","LU2476274308.USD","VTHR","BK1197","01789","KCE","LU2778985437.USD","LU0640798160.USD","02196","IE00B5MMRT66.SGD","LU1770034418.SGD","SG9999004311.SGD","LU0417516738.SGD","LU0348827113.USD","LU1719994722.HKD","ARTY","LU0348825331.USD","BK1191","01530","02367","LU1303224171.USD","LU0348783233.USD","AIPO","02268","AGIX","LU0634319403.HKD","LU2328871848.SGD","01477","09688","LU0540923850.HKD","601066","LU2476274720.SGD","03933","06821","KURE","LU1961090484.USD","LU0348766576.USD","LU0828237510.HKD","LU0561508036.HKD","06160","09926","BK1585","QTOC","BK1515","02228","LU0417516571.SGD","CHAT","BK1500","01099","LU0348784397.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167909731","title":"财报前瞻｜晶泰控股本季度营收暂无一致预测，机构观点尚不明确","url":"https://stock-news.laohu8.com/highlight/detail?id=1167909731","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167909731?lang=zh_cn&edition=full","pubTime":"2026-08-12 08:40","pubTimestamp":1786495217,"startTime":"0","endTime":"0","summary":"晶泰控股将于2026年08月19日披露最新季度财报，本文围绕市场预测、上季度回顾及本季度展望进行梳理。由于公开渠道尚未形成一致预期，当前未获取到对本季度营收、毛利率、净利润或净利率、调整后每股收益的量化预测；公司上季度财报文本中关于本季度的具体指引亦未检索到有效数据。近期主流机构对晶泰控股的季度前瞻观点尚未形成明确多数派结论，未检索到足以统计看多或看空比例的分析师报告，因而难以界定市场的偏向性观点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜晶泰控股本季度营收暂无一致预测，机构观点尚不明确","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","BK1583","LU2242644610.SGD","09688","LU1303224171.USD","09969","LU1226287792.SGD","MEDX","LU0072913022.USD","06978","BK1576","LU1152091168.USD","LU1226288170.HKD","LU2328871848.SGD","02268","BK1521","LU1813983027.USD","06160","LU0315179316.USD","LU1993786604.SGD","HK0000306685.HKD","BK1161","BK1617","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","IBBQ","01548","LU0880133367.SGD","LU1226287875.USD","BK1515","LU2125910500.SGD","KURE","IE00BZ08YT58.USD","LU2488822045.USD","LU0326950275.SGD","01093","HK0000320223.HKD","BK1500","06855","BK1588","IE00B031HY20.USD","02410","159992","IE00B543WZ88.USD","03692","LU1951186391.HKD","IE00B5MMRT66.SGD","LNGR","LU2039709279.SGD","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198305012","title":"异动解读 | 晶泰控股盘中大涨5.04%，AI平台发布及大行唱好持续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1198305012","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198305012?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:38","pubTimestamp":1786412305,"startTime":"0","endTime":"0","summary":"晶泰控股（02228）今日盘中股价大幅拉升，一度涨超5%，延续近期的强势表现，引发市场广泛关注。消息面上，公司近日正式发布XtalPi Science科学智能平台，并联合26家机构发起“科学智能开放生态联盟”，市场对其估值逻辑由CRO服务商向AI平台型公司切换的预期持续升温。同时，摩根大通首次给予公司“增持”评级，浙商证券维持“买入”评级，并指出剔除一次性管线影响后主业同比增长65%，机构看多共识进一步巩固。此外，公司将于近期召开董事会审议中期业绩，业绩窗口期临近亦吸引资金关注。板块层面，生命科学工具和服务行业今日整体走强，AI制药赛道资金共振对公司股价形成正向带动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197408322","title":"异动解读｜晶泰控股盘中上涨5.6%，AI平台发布及大行唱好延续催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1197408322","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197408322?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:36","pubTimestamp":1786412206,"startTime":"0","endTime":"0","summary":"8月11日，晶泰控股盘中上涨5.6%，报8.585港元，成交额1.16亿港元，延续前一交易日强势表现。消息面上，公司近日正式发布XtalPi Science科学智能平台，并联合26家机构发起\"科学智能开放生态联盟\"，市场对其估值逻辑由CRO服务商向AI平台型公司切换的预期持续升温。板块层面，生命科学工具和服务行业今日整体走强，康龙化成涨3.06%、药明康德涨2.22%、金斯瑞生物科技涨1.74%，AI制药赛道资金共振对公司股价形成正向带动。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658097936","title":"AI医疗概念股普升 剂泰科技-P（07666）涨12.86%、晶泰控股（02228）涨10.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658097936","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658097936?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:03","pubTimestamp":1786327392,"startTime":"0","endTime":"0","summary":"金吾财讯 | AI医疗概念股盘初普升，截至发稿，剂泰科技-P 涨12.86%，晶泰控股涨10.26%，英硅智能涨9.38%，百奥赛图-B涨8.33%，讯飞医疗科技涨4.98%，医渡科技涨4.00%，云知声涨3.96%，平安好医生涨3.58%，阿里健康涨3.21%，京东健康涨2.98%。AIDD有望重塑早期药物发现的流程，大大加速早期药物筛选的效率及成功率，相关干实验投入的增加以及对湿实验需求持续的增长，有望为下游产业链持续带来增量。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/NDQ1MWJhN2NhODAzMzgwYTAyY2UxMDMzODA5NjE3NDc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NDQ1MWJhN2NhODAzMzgwYTAyY2UxMDMzODA5NjE3NDc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987779","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1518","BK1515","BK1142","159891","AIPO","02506","BK1189","02158","BK1502","SGXZ62798434.SGD","VTHR","BK1589","86618","BK1141","BK1571","BK1584","BK1591","03696","HK0000165453.HKD","02228","AGIX","BK1501","07666","LU0051755006.USD","BK1109","SGXZ86797644.SGD","BK1617","00241","02315","BK1219","BK1615","LU0456827905.SGD","BK1161","01833","09678","06618","CHAT","BK1610","BK1247","QTOC","BK1583","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121716613","title":"异动解读 | 晶泰控股盘中大涨9.87%，AI平台发布叠加板块共振及大行唱好","url":"https://stock-news.laohu8.com/highlight/detail?id=1121716613","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1121716613?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:54","pubTimestamp":1786326871,"startTime":"0","endTime":"0","summary":"晶泰控股(02228)今日盘中股价大涨9.87%，引发市场广泛关注。消息面上，公司近日正式发布XtalPi Science科学智能平台，并联合26家机构发起“科学智能开放生态联盟”，市场对其估值逻辑由CRO服务商向AI平台型公司切换的预期显著升温。同时，摩根大通近期首予公司“增持”评级，浙商证券维持“买入”评级并指出剔除一次性管线影响后主业同比增长65%，进一步提振了投资者信心。此外，公司即将召开董事会审议中期业绩，业绩窗口期临近亦吸引了资金关注。板块层面，生命科学工具和服务行业今日整体走强，AI制药赛道资金共振明显，对晶泰控股的股价也形成了正向带动。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183371391","title":"异动解读｜晶泰控股盘中上涨7.28%，AI制药板块集体走强叠加平台发布催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1183371391","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183371391?lang=zh_cn&edition=full","pubTime":"2026-08-10 09:31","pubTimestamp":1786325469,"startTime":"0","endTime":"0","summary":"8月10日，晶泰控股盘中上涨7.28%，报8.11港元，成交额3678.24万港元。消息面上，公司近日正式发布XtalPi Science科学智能平台，并联合26家机构发起\"科学智能开放生态联盟\"，市场对其估值逻辑由CRO服务商向AI平台型公司切换的预期升温。此外，公司8月19日将召开董事会审议中期业绩，业绩窗口期临近亦提振资金关注。板块层面，生命科学工具和服务行业今日整体走强，英矽智能涨9.6%、金斯瑞生物科技涨7.4%、药明生物涨5.02%，AI制药赛道资金共振明显。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://www.xtalpi.com","stockEarnings":[{"period":"1week","weight":-0.0143},{"period":"1month","weight":0.1193},{"period":"3month","weight":-0.0777},{"period":"6month","weight":-0.2664},{"period":"1year","weight":-0.2445},{"period":"ytd","weight":-0.1966}],"compareEarnings":[{"period":"1week","weight":-0.0163},{"period":"1month","weight":-0.0086},{"period":"3month","weight":0.016},{"period":"6month","weight":-0.0393},{"period":"1year","weight":0.0234},{"period":"ytd","weight":-0.0018}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"晶泰控股有限公司是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司。该公司主要经营两个业务。药物发现解决方案业务从事就新型药物发现工作为各类生物技术与制药公司和学术机构提供模块独立解决方案或与之合作。智能自动化解决方案业务从事提供固态研发服务及自动化化学合成服务。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.06643},{"month":2,"riseRate":0.285714,"avgChangeRate":0.016028},{"month":3,"riseRate":0,"avgChangeRate":-0.069153},{"month":4,"riseRate":0.666667,"avgChangeRate":0.048494},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.010585},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.023767},{"month":7,"riseRate":0.428571,"avgChangeRate":0.047576},{"month":8,"riseRate":0.5,"avgChangeRate":-0.032189},{"month":9,"riseRate":0.8,"avgChangeRate":0.065839},{"month":10,"riseRate":0.6,"avgChangeRate":0.092453},{"month":11,"riseRate":0.5,"avgChangeRate":0.05299},{"month":12,"riseRate":0.5,"avgChangeRate":-0.011625}],"exchange":"SEHK","name":"晶泰控股","nameEN":"XTALPI"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"晶泰控股,02228,晶泰控股股票,晶泰控股股票老虎,晶泰控股股票老虎国际,晶泰控股行情,晶泰控股股票行情,晶泰控股股价,晶泰控股股市,晶泰控股股票价格,晶泰控股股票交易,晶泰控股股票购买,晶泰控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}